Sanofi ADR
USUSDSanofi ADR (PA:SAN) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 6. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.
O podjetju
- Spletna stran
- sanofi.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sedež
- PARIS, France
- Izvršni direktor
- Paul Hudson
- Zaposleni
- 106 566
- Ustanovljena
- 2004
- Na borzi od
- 03.01.2000 (PA:SAN)
- Delnice v obtoku
- 1.22 mrd. na dan 2025-12-31
- Prosto prenosljive delnice
- 2.16 mrd.
- Tržna kapitalizacija
- 98.67 mrd. USD
- Notranje osebe
- 0%
- Institucionalni vlagatelji
- 8.02%
- Panoga (SIC)
- Pharmaceutical Preparations
- Pravna oblika
- QVPB
- ISIN
- FR0000120578
- LEI
- 549300E9PC51EN656011
- Delež izplačila
- ≈64.0%
- FCF
- 10.8 mrd. EUR47%
- Dolg
- 18.7 mrd. EUR1.0 let FCF
- Dividendni staž
- 23 let
- Dobički, FCF in izplačane dividende — za 12 mesecev do 31.12.2025 (najnovejše poročilo podjetja).
Opis
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Borze in oznake
| Borza | Oznaka | Valuta | Cena | Vrsta |
|---|---|---|---|---|
| US USA Stocks | SNYNF OTC | USD | 78.99 -1.19% | navadne delnice |
| LSE London Stock Exchange | 0O59 IOB | EUR | 71.63 +0.72% | navadne delnice |
| MI Borsa Italiana (Milan) | 1SAN dodatna | EUR | 71.64 +0.90% | navadne delnice |
| PA Euronext Paris | SAN glavna | EUR | 71.52 +0.83% | navadne delnice |
| VI Vienna Stock Exchange | SANO dodatna | EUR | 71.3 +1.03% | navadne delnice |
| XETRA Xetra | SNW dodatna | EUR | 71.78 -1.21% | navadne delnice |
Dividende
Sanofi ADR (SAN) izplačuje dividende enkrat letno. Na leto (12 mesecev do in vključno z najnovejšim napovedanim plačilom): 4.12 EUR na delnico (plačila: 1). To je približno 5.76% trenutne cene delnice. Glede na zgodovino izplačil se naslednji datum ex-dividende pričakuje okoli 04.05.2027. Leta neprekinjenih dividend: 23.
| Ex-datum | Izplačilo | Znesek | % | Vrsta | Oznaka |
|---|---|---|---|---|---|
| 2026-05-05 | 2026-05-07 | 4.1200 EUR | 5.8/5.8 % | letno | PA:SAN |
| 2025-05-12 | 2025-05-14 | 3.9200 EUR | 5.5/5.5 % | letno | PA:SAN |
| 2024-05-13 | — | 3.7600 EUR | 5.3/10.2 % | letno | PA:SAN |
| 2023-05-30 | — | 3.5600 EUR | 5.0/5.0 % | letno | PA:SAN |
| 2022-05-06 | — | 3.3300 EUR | 4.7/4.7 % | letno | PA:SAN |
Največji imetniki
| Imetnik | Delež | Delnice | Datum poročila |
|---|---|---|---|
| Dodge & Cox Inc. | 10.54% | 28.09 mio. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 7.84% | 20.9 mio. | 2026-06-30 |
| Morgan Stanley | 4.02% | 10.7 mio. | 2026-06-30 |
| Fisher Asset Management,… | 3.99% | 10.63 mio. | 2026-06-30 |
| Bank of America Corporat… | 3% | 8.01 mio. | 2026-06-30 |
| Invesco Ltd. | 2.55% | 6.8 mio. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.47% | 6.57 mio. | 2026-06-30 |
| Mondrian Investment Part… | 2.07% | 5.52 mio. | 2026-06-30 |
| Brandes Investment Partn… | 1.55% | 4.14 mio. | 2026-06-30 |
| AIM Sector Funds (Invesc… | 1.51% | 4.03 mio. | 2026-04-30 |
| Federated Hermes, Inc. | 1.44% | 3.85 mio. | 2026-06-30 |
| Boston Partners | 1.44% | 3.84 mio. | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 1.31% | 15.85 mio. | 2026-07-31 |
| Putnam ETF Trust-Putnam… | 1.26% | 3.36 mio. | 2026-05-31 |
| VANGUARD TAX-MANAGED FUN… | 0.87% | 10.53 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 8.11 mio. | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.63% | 1.67 mio. | 2026-06-30 |
| AMERICAN MUTUAL FUND | 0.59% | 1.58 mio. | 2026-06-30 |
| American Century Capital… | 0.37% | 976 561 | 2026-06-30 |
| Bridge Builder Trust-Bri… | 0.36% | 967 100 | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 4.24 mio. | 2026-07-31 |
| VanEck ETF Trust-VanEck… | 0.35% | 938 561 | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.33% | 4.04 mio. | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 3.89 mio. | 2026-08-31 |
| Capital World Growth & I… | 0.3% | 3.67 mio. | 2026-06-30 |
| -Victory Pioneer Core Eq… | 0.3% | 799 487 | 2026-06-30 |
| Fidelity Covington Trust… | 0.3% | 797 184 | 2026-08-31 |
| NEW PERSPECTIVE FUND | 0.29% | 3.56 mio. | 2026-06-30 |
| Federated Hermes Eqy. Fd… | 0.29% | 3.48 mio. | 2026-07-31 |
| Bridge Builder Trust-Bri… | 0.29% | 3.44 mio. | 2026-06-30 |
| Pacer Advisors, Inc. | 0.1% | 1.16 mio. | 2026-06-30 |
| Generali Investments Cee… | 0% | 29 339 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 19 200 | 2026-06-30 |
| Gamma Investing LLC | 0% | 58 | 2026-06-30 |
| L'Oréal | — | — | — |
